ID
22797
Beskrivning
Study ID: 100310 Clinical Study ID: RRL100310 Study Title: A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of intermittent dosing of ropinirole in patients with Restless Legs Syndrome (RLS) Part 1: Visit 8 (Week 15) PRN Subject Diary Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00225862 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome More details on: https://clinicaltrials.gov/ct2/show/NCT00225862
Länk
https://clinicaltrials.gov/ct2/show/NCT00225862
Nyckelord
Versioner (2)
- 2017-06-01 2017-06-01 -
- 2017-06-12 2017-06-12 -
Uppladdad den
12 juni 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862
Beskrivning
RLS episode
Alias
- UMLS CUI-1
- C0035258
- UMLS CUI-2
- C0332189
Similar models
Intermittent Ropinirole in Restless Legs Syndrome (RLS) NCT00225862
C1955348 (UMLS CUI-2)
C0035258 (UMLS CUI-3)
C0035258 (UMLS CUI [1,2])
C0332189 (UMLS CUI [1,3])
C0035258 (UMLS CUI [1,2])
C0332189 (UMLS CUI [1,3])
Inga kommentarer